Events
Events
2018
-
August 27-28, 2018
Cambridge Healthtech Institute’s 3rd Annual Oncolytic Virus Immunotherapy: Commercializing the Exciting Potential of Oncolytic Virotherapy
Boston, MA
Stephen J. Russell, M.D., Ph.D., Vyriad CEO, presentation: “Progress with Oncolytic Vesicular Stomatitis Viruses”.
-
June 26-28, 2018
Armed Oncolytic Immunotherapies Summit
Frankfurt, Germany
Stephen J. Russell, M.D., Ph.D., Vyriad CEO, presentation: “Systemic Cancer Therapy Using Oncolytic VSVs: The Voyager Platform” and participate in a Panel Discussion: Explore Novel Approaches to Identify the Most Rational Combinations “
-
June 1-5, 2018
American Society of Clinical Oncology (ASCO) Annual Meeting
Chicago, Illinois
Alice Bexon, M.D., Vyriad CMO will be attending the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
-
May 16-19, 2018
18th Annual American Society of Cell & Gene Therapy (ASGCT) meeting
Chicago, IL
Stephen J. Russell, M.D., Ph.D., Vyriad CEO, has been elected Vice-President of ASGCT. ASGCT has elected four new members to the Board of Directors, including Dr. Stephen J. Russell as new incoming vice president. Dr. Russell will serve a yearlong term as vice president before serving as ASGCT's president-elect and, finally, president through the 2021 annual meeting. Dr. Russell will be Co-Chairing: Clinical Trials Spotlight I at the annual meeting.
Kah-Whye Peng, Ph.D., Vyriad Chief Technology Officer, has been invited to present: Use of Novel Transgenic NIS Reporter Rats for Longitudinal Tracking of Fibrogenesis by High-Resolution Imaging and Use of Novel Transgenic NIS Reporter Rats for Longitudinal Tracking of Fibrogenesis by High-Resolution Imaging
-
April 9-12, 2018
International Oncolytic Virus Conference
Oxford, UK
Stephen J. Russell, M.D., Ph.D., Vyriad CEO, has been invited to Chair, Innate and collateral adaptive tumor immunity. Dr. Russell will also participate in Steve Russell (Once should be enough!) vs. Alan Melcher (Repeat dosing is crucial!)
Kah-Whye Peng, Ph.D., Vyriad Chief Technology Officer, has been invited to Chair, Translation, imaging and clinical breakthroughs. Dr. Peng will be presenting: Oncolytic virus encoding IFNbeta: optimizing therapeutic index.
2017
-
December 5-7, 2017
Oncolytic Virotherapy Summit
Miami, Florida
Stephen J. Russell, M.D., Ph.D., Vyriad CEO, was invited as a panel member for: How Can We Improve the Efficacy of Oncolytic Virotherapies? Dr. Russell also provided a presentation entitled “VSV-IFNb-NIS and MV-NIS: A Tale of Two Paradigms” and managed a workshop entitled “Optimizing Oncolytic Viruses: Identifying the Right Viral Platform”
-
November 28-29, 2017
28th Annual Piper Jaffray Healthcare Conference
New York, New York
Stephen J. Russell, M.D., Ph.D., Vyriad CEO, presented “Oncolytic Virotherapy: The Next Major Breakthrough in Cancer Treatment” at the 28th Annual Piper Jaffray Healthcare Conference
-
November 8-12, 2017
The 32nd Annual Society for Immunotherapy of Cancer (SITC) meeting
National Harbor, Maryland
Stephen J. Russell, M.D., Ph.D., Vyriad CEO, attended the annual SITC meeting
-
November 4, 2017
Dr. Boenjamin Setiawan Distinguished Lectureship for 2017
Jakarta, Indonesia
Stephen Russell, M.D., Ph.D., Vyriad CEO, was invited to present on “Oncolytic Viruses: An Emerging Cornerstone for Immuno-oncology” at the Dr. Boenjamin Setiawan Distinguished Lecture Series
-
February 23-25, 2017
ASCO-SITC Clinical Immuno-Oncology Symposium
Orlando, Florida
Stephen J Russell from Vyriad was invited to present on "Viral Therapy" at the ASCO-SITC conference on exploiting viruses for cancer therapy in combination with immune modulators.
2016
-
October 1-4, 2016
the 10th International Meeting on Replicating Oncolytic Virus Therapeutics
Vancouver, Canada
Kah-Whye Peng, PhD, CTO of Vyriad gave a Plenary presentation entitled “Vesicular stomatitis virus (VSV) as an oncolytic agent”
Stephen J. Russell, MD, PhD, CEO & President of Vyriad gave a Plenary presentation entitled “Measles as a versatile oncolytic agent”
-
June 18, 2016
35th Annual Meeting of the American Society of Virology
Blacksburg, VA
Keynote Lecture: “Oncolytic Viruses: Past, Present, and Future”
Stephen J. Russell, MD, PhD, CEO & President, Vyriad